Japanese

Usefulness of Aripiprazole in the Treatment of Delirium Takuya YOSHIIKE 1,2 , Takashi TAKEUCHI 1 , Takeshi SASAKI 1 , Hiroyo ISHIKAWA 3 , Munehisa FUJITA 1 , Hidenori ATSUTA 4 , Hidekazu MASAKI 5 , Masaki NISHIDA 1 , Tomoaki YUKIZANE 1 , Kazunari OSHIMA 3 , Atsushi KASHIWA 6 , Naoki YAMAMOTO 1 , Akeo KURUMAJI 1 , Toru NISHIKAWA 1 1Section of Psychiatry and Behavioral Science, Tokyo Medical and Dental University Graduate School, Tokyo, Japan 2Department of Psychiatry, Yokohama City Minato Red Cross Hospital 3Ohmiya Kousei Hospital 4Department of Psychiatry, Tokyo Metropolitan Hiroo Hospital 5Department of Psychiatry, Tokyo Metropolitan Tama Medical Center 6Heart Clinic Yokohama Keyword: Aripiprazole , Atypical antipsychotics , Delirium pp.543-549
Published Date 2011/6/15
DOI https://doi.org/10.11477/mf.1405101889
  • Abstract
  • Look Inside
  • Reference

 Atypical antipsychotics have been widely used for the treatment of delirium. However, there are only few reports on clinical trials of aripiprazole for its use in the treatment of delirium. In the present study, we describe the efficacy and safety of aripiprazole in the patients with delirium. Seventeen patients with ICD-10 delirium were administered open-label aripiprazole. To evaluate the efficacy of aripiprazole, the scores of 13 severity items of the Japanese version of the Delirium Rating Scale-Revised-98 were assessed. Aripiprazole was effective in 76.5% (13/17) of the patients. The initial dose of aripiprazole was 5.8±0.8 mg/day, and the maximum dose was 8.1±3.3mg/day. The maximum treatment response was achieved at 5.4±4.6days. Lightheadedness (17.6%) and somnolence (11.8%) were observed;however, there were no serious adverse effects. These results suggest the efficacy and safety of using aripiprazole in the treatment of delirium. To verify these preliminary findings, further controlled comparison studies are needed.


Copyright © 2011, Igaku-Shoin Ltd. All rights reserved.

基本情報

電子版ISSN 1882-126X 印刷版ISSN 0488-1281 医学書院

関連文献

もっと見る

文献を共有